SUMITOMO PHARMA CO. LTD. financial statements, including revenue, expenses, profit, and loss

The total revenue of DPM for the last quarter is 486.98 M EUR, and it's 7.94% lower compared to the previous quarter. The net income of Q4 23 is -1.21 B EUR.